Actively Recruiting
Histotripsy for Ablation of Liver Tumours in Asia
Led by National Cancer Centre, Singapore · Updated on 2026-02-23
40
Participants Needed
3
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.
CONDITIONS
Official Title
Histotripsy for Ablation of Liver Tumours in Asia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 years or older at the time of consent
- Histologically or cytologically confirmed primary or secondary liver cancers, including imaging diagnosis for HCC
- Liver-limited malignancies not eligible for or declined surgery or other local treatments
- Patients with solid cancers on systemic therapy having up to 3 progressive liver lesions no larger than 3 cm
- Up to 3 hepatic lesions visible and targetable by ultrasound
- ECOG Performance Status of 0 or 1
- Child-Pugh class A or B7 liver function for patients with cirrhosis
- Adequate blood counts and organ function within 14 days before treatment
- Ability to undergo general anesthesia as confirmed by pre-anaesthetic assessment
- Life expectancy of at least 3 months
- Willing and able to comply with study visits and procedures
- Provided written informed consent prior to study procedures
You will not qualify if you...
- Extrahepatic disease progression needing immediate systemic treatment, including brain metastases or malignant ascites
- Vascular invasion involving major portal or hepatic veins
- Tumors located within 5 mm of hollow organs where treatment risk is high
- Lesions not well seen or reachable by ultrasound due to ribs or gas
- Severe or uncontrolled medical conditions like hypertension, cardiovascular disease, active infection, or severe lung disease
- Contraindications to general anesthesia or surgery
- Pregnancy or breastfeeding; women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment
- Participation in another interventional or therapeutic trial within 4 weeks before enrollment
- Any condition that may affect patient safety or study adherence as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
National University Hospital
Singapore, Singapore, 119074
Not Yet Recruiting
2
National Cancer Centre Singapore
Singapore, Singapore, 168583
Actively Recruiting
3
Singapore General Hospital
Singapore, Singapore, 169608
Actively Recruiting
Research Team
P
Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS
CONTACT
S
Sandra Hsing
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here